TDC
GNMX

Thompson Davis & Co’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Thompson Davis & Co’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-250
Closed -$2K – 1290
2015
Q2 		$2K Hold
250
– – ﹤0.01% 1108
2015
Q1 		$2K Buy
+250
New +$1.89K ﹤0.01% 1103
2014
Q2 		– Sell
-750
Closed -$5K – 898
2014
Q1 		$5K Buy
+750
New +$5.86K 0.01% 645

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thompson Davis & Co's GNMX Position: Q3 2015 in Review

Thompson Davis & Co sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2015, closing a stake of 250 shares — an estimated $2K sold.

Thompson Davis & Co first reported a position in GNMX in Q1 2014 and held it in 3 quarters. The position peaked at $5K in Q1 2014. 51 funds tracked by Wall St. Rank hold GNMX as of Q3 2015.

  • Thompson Davis & Co reported no remaining Aevi Genomic Medicine Inc position as of Q3 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 250 Aevi Genomic Medicine Inc shares in Q3 2015, an estimated $2K.
  • Thompson Davis & Co first reported a position in Aevi Genomic Medicine Inc in Q1 2014 and held it in 3 quarters.
  • Thompson Davis & Co's Aevi Genomic Medicine Inc position peaked at $5K in Q1 2014.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2015.

Based on Thompson Davis & Co's 13F filing for Q3 2015, filed 30 Oct 2015.